Noven Pharmaceuticals, Inc. FDA Record
- Latest inspection VAI · Aug 24, 2026
- Last warning letter 2016
Noven Pharmaceuticals, Inc. has 51 FDA recalls, 14 inspections, 0 510(k) clearances and 2 compliance actions on record. FDA has issued 2 warning letters to Noven Pharmaceuticals, Inc., the most recent on Aug 5, 2016.
- Latest recall
- D-0055-2025 · Class II · Oct 31, 2024
- Latest inspection
- Aug 24, 2026 · VAI
Summary
| Records | Count | Last refreshed | Source as of | Status |
|---|---|---|---|---|
| Recalls | 51 | Nov 15, 2026 | File dated Nov 10, 2026 | Current |
| 510(k) clearances | 0 | Nov 15, 2026 | File dated Nov 9, 2026 | Current |
| Inspections | 14 | Nov 17, 2026 | Newest record Nov 9, 2026 | Current |
| Compliance actions | 2 | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
FDA record by year
Noven Pharmaceuticals, Inc.: FDA inspections per year
| Year | Inspections | OAI | Warning letters | Recall records | Class I |
|---|---|---|---|---|---|
| 2026 | 2 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 1 | 0 |
| 2023 | 0 | 0 | 0 | 4 | 0 |
| 2022 | 0 | 0 | 0 | 3 | 0 |
| 2021 | 1 | 0 | 0 | 10 | 0 |
| 2020 | 0 | 0 | 0 | 0 | 0 |
| 2019 | 0 | 0 | 0 | 0 | 0 |
| 2018 | 1 | 0 | 0 | 7 | 0 |
| 2017 | 0 | 0 | 0 | 5 | 0 |
Reviewing Noven Pharmaceuticals, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Noven Pharmaceuticals, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Noven Pharmaceuticals, Inc. FDA Warning Letters
| Issued | Subject | Issuing office | Close-out letter |
|---|---|---|---|
| Aug 5, 2016 · Record page | |||
| Aug 25, 2011 · Record page |
Recent recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0055-2025 | Class II | Xelstrym (dextroamphetamine) transdermal system, 13.5 mg dextroamphetamine/9 hours, 30 individually… | Oct 31, 2024 |
| D-0471-2023 | Class II | Daytrana (methylphenidate transdermal system) CII, 15 mg, 30-count carton, Rx only, Manufactured for… | Mar 10, 2023 |
| D-0470-2023 | Class II | Daytrana (methylphenidate transdermal system) CII, 10mg, 30-count carton, Rx only, Manufactured for… | Mar 10, 2023 |
| D-0472-2023 | Class II | Daytrana (methylphenidate transdermal system) CII, 20mg, 30-count carton, Rx only, Manufactured for… | Mar 10, 2023 |
| D-0473-2023 | Class II | Daytrana (methylphenidate transdermal system) CII, 30 mg, 30-count carton, Rx only, Manufactured for… | Mar 10, 2023 |
| D-0071-2023 | Class II | Daytrana (methylphenidate transdermal system), Delivers 15 mg over 9 hours, (1.6 mg/hr), 30 patches… | Nov 16, 2022 |
| D-1169-2022 | Class II | Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Contains: 30… | Jun 24, 2022 |
| D-0889-2022 | Class II | Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Contains: 30… | May 6, 2022 |
| D-0724-2021 | Class II | Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.14 mg per day, 50/140 Twice… | Jul 30, 2021 |
| D-0725-2021 | Class II | Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.25 mg per day 50/250 Twice… | Jul 30, 2021 |
| D-0394-2021 | Class II | Daytrana (methylphenidate transdermal system), Delivers 15 mg over 9 hours (1.6 mg/hr), 30 Patches… | May 20, 2021 |
| D-0393-2021 | Class II | Daytrana (methylphenidate transdermal system), Delivers 10 mg over 9 hours (1.1 mg/hr), 30 Patches… | May 20, 2021 |
| D-0337-2021 | Class II | Estradiol Transdermal System Delivers 0.0375 mg/day, 8 Systems/box, Rx only, Mfd. by: Noven… | Apr 16, 2021 |
| D-0336-2021 | Class II | Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, Mfd. by… | Apr 16, 2021 |
| D-0295-2021 | Class II | Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30… | Feb 19, 2021 |
| D-0294-2021 | Class II | Daytrana (methylphenidate transdermal system), Delivers 15 mg over 9 hours (1.6 mg/hr), Contains: 30… | Feb 19, 2021 |
| D-0293-2021 | Class II | Daytrana (methylphenidate transdermal system), Delivers 10 mg over 9 hours (1.1 mg/hr), Contains: 30… | Feb 19, 2021 |
| D-0296-2021 | Class II | Daytrana (methylphenidate transdermal system) Delivers 30 mg over 9 hours (3.3 mg/hr) Contains: 30… | Feb 19, 2021 |
| D-1208-2018 | Class II | Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count… | Sep 7, 2018 |
| D-1207-2018 | Class II | Minivelle (estradiol transdermal system) Patches Delivers 0.1 mg/day, a) 2 count and b) 8 count… | Sep 7, 2018 |
Recent FDA inspections
| Date | Site | Product | Classification | FEI |
|---|---|---|---|---|
| Aug 24, 2026 | Miami, FL | Drugs | Voluntary Action Indicated (VAI) | 1000222037 |
| Feb 13, 2026 | Miami, FL | Drugs | No Action Indicated (NAI) | 1000222037 |
| Nov 17, 2021 | Miami, FL | Drugs | Voluntary Action Indicated (VAI) | 1000222037 |
| Jan 26, 2018 | Miami, FL | Drugs | Voluntary Action Indicated (VAI) | 1000222037 |
| Jan 13, 2016 | New York, NY | Drugs | No Action Indicated (NAI) | 3008855976 |
| Jul 10, 2015 | Miami, FL | Drugs | Official Action Indicated (OAI) | 1000222037 |
| Apr 24, 2013 | Carlsbad, CA | Drugs | No Action Indicated (NAI) | 3005201285 |
| Mar 6, 2013 | New York, NY | Drugs | No Action Indicated (NAI) | 3008855976 |
| Sep 24, 2012 | Miami, FL | Drugs | No Action Indicated (NAI) | 1000222037 |
| Aug 2, 2012 | Carlsbad, CA | Drugs | No Action Indicated (NAI) | 3005201285 |
| Jun 4, 2012 | Miami, FL | Drugs | No Action Indicated (NAI) | 1000222037 |
| Feb 14, 2011 | Carlsbad, CA | Drugs | Official Action Indicated (OAI) | 3005201285 |
| May 6, 2010 | Miami, FL | Drugs | Voluntary Action Indicated (VAI) | 1000222037 |
| Feb 6, 2009 | Miami, FL | Drugs | No Action Indicated (NAI) | 1000222037 |
- NAI
- No objectionable conditions or practices were found during the inspection.
- VAI
- Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
- OAI
- Regulatory and/or administrative actions are recommended.
Compliance Actions
FDA's compliance actions data lists 2 compliance actions under Noven Pharmaceuticals, Inc.: warning letters, injunctions and seizures. None came from FDA's Center for Tobacco Products.
FDA-inspected facilities
| Facility | Location | Inspections | Latest |
|---|---|---|---|
| FEI 1000222037 | Miami, FL | 9 | Aug 24, 2026 |
| FEI 3008855976 | New York, NY | 2 | Jan 13, 2016 |
| FEI 3005201285 | Carlsbad, CA | 3 | Apr 24, 2013 |
Noven Pharmaceuticals, Inc. and the FDA: common questions
Has Noven Pharmaceuticals, Inc. received an FDA warning letter?
Yes. FDA has issued 2 warning letters to Noven Pharmaceuticals, Inc.. The most recent is dated Aug 5, 2016.
Has Noven Pharmaceuticals, Inc. received an FDA Form 483?
FDA has not published a Form 483 for "Noven Pharmaceuticals, Inc." in its reading room. FDA publishes some Form 483s, not all of them.
When did the FDA last inspect Noven Pharmaceuticals, Inc.?
The most recent FDA inspection on file ended Aug 24, 2026 at Miami, FL and was classified VAI. FDA has 14 inspections of Noven Pharmaceuticals, Inc. on file, 2 of them classified OAI (official action indicated).
Has Noven Pharmaceuticals, Inc. had an FDA recall?
Yes. Noven Pharmaceuticals, Inc. has 51 FDA recalls on record. The most recent started Oct 31, 2024.
Need more than this page shows? Ask about Noven Pharmaceuticals, Inc. in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.